The modest decline continues a volatile week for UNH, which dropped sharply on Tuesday when the Senate report first surfaced, rebounded Wednesday-Thursday on positive rural hospital news, and now gives back some gains as the regulatory overhang persists. The below-average volume (0.7x) suggests this is more of a drift lower on lingering concerns rather than new institutional selling. Trump's 'Great Healthcare Plan' targeting PBM kickbacks adds another layer of regulatory uncertainty for UnitedHealth's Optum Rx business.
This is a permanent link to this specific analysis (ID: 2227)
Back to Dashboard